Background Biosimilars reduce the burden of cost on patients and payers, and so doing,
increase access to life-saving care. However, biosimilar uptake in the US has been …

Equally safe and effective alternatives to biological reference products, biosimilars, can lead
to lowered treatment costs and higher patient access. With the arrival of biosimilars in the …

Purpose An overview of therapeutic oncology biosimilars, the US biosimilars regulatory
pathway, and the clinical development of selected biosimilar products is provided, including …

The Patient Protection and Affordable Care Act of 2010 included the Biologics Price
Competition and Innovation Act (BPCI Act), which enables the introduction of biosimilar …

Background Biosimilars have the potential to increase patient access and significantly
reduce healthcare costs in the US. However, uptake in the US has been slower than …

Biological drugs are vital but often high-cost components of cancer treatment. Several
biosimilar versions of these drugs have been approved in Europe and/or the USA, with …

An increasing availability of biosimilars is an important step in the process of delivering
optimal care while improving access for patients with cancer. Evolving regulatory …

Purpose Biosimilars are a cost‐effective alternative to biologics that could improve patients'
access to expensive biological medicines. Currently, there are little data on doctors' …

This article discusses specific issues related to the market access of biosimilars.
Biopharmaceuticals are complex molecules produced by living cells. Copies of these …

Biologics are significant drivers of globally escalating healthcare costs. Biosimilars have
potential to offer cost savings with comparable efficacy and safety to innovator products and …